The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.49

Today's change+0.10 +0.54%
Updated September 4 10:55 AM EDT. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.49

Today's change+0.10 +0.54%
Updated September 4 10:55 AM EDT. Delayed by at least 15 minutes.

Meridian Bioscience Inc crosses above 20-day moving average

Meridian Bioscience Inc is up today by (U.S.)$0.10 or 0.54% to (U.S.)$18.49 and crossing above its 20-day moving average. Shares have lost 3.24% over the last five days, but have gained 12.33% over the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $18.19
  • Previous close(U.S.) $18.39
  • High(U.S.) $18.58
  • Low(U.S.) $18.18
  • Bid / Ask(U.S.) $18.44 / (U.S.) $18.50
  • YTD % change+12.33%
  • Volume22,647
  • Average volume (10-day)275,746
  • Average volume (1-month)213,006
  • Average volume (3-month)221,242
  • 52-week range(U.S.) $15.56 to (U.S.) $20.28
  • Beta1.15
  • Trailing P/E22.03×
  • P/E 1 year forward21.35×
  • Forward PEG1.26×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.33%
  • Trailing EPS(U.S.) $0.84
Updated September 4 10:55 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.13%

Based on its net profit margin of 18.13%, Meridian Bioscience Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.91%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue48524847
Total other revenue--------
Total revenue48524847
Gross profit30332928
Total cost of revenue18191918
Total operating expense34363535
Selling / general / administrative13131313
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income14161312
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax14161212
Income after tax91088
Income tax, total5544
Net income91088
Total adjustments to net income--------
Net income before extra. items91088
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items91088
Inc. avail. to common incl. extra. items91088
Diluted net income91088
Dilution adjustment--------
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.220.240.190.20
Dividends per sharevalue per share0.200.200.200.20
Diluted normalized EPSvalue per share0.220.240.190.20